Lumida
/NUVL
⌘K
Nuvalent Inc

Nuvalent Inc

NUVL
$123.96USD+0.00%+0.00 today

MARKET CAP

9.8B

P/E (TTM)

FWD P/E

DAY RANGE

$124 – $124

52W RANGE

$124
$124

AI Summary

Stalk
Sell NowHigh

NUVL is in a Stage 4 decline with sequential lower highs and lower lows and is trading below all major EMAs and moving averages. The active Support Failure and Lower Highs & Lower Lows patterns confirm supply dominance and ongoing downtrend. With no signs of stabilization, EMA repair, or volatility contraction, selling into rallies at the 9EMA/20EMA and 50DMA is the preferred execution posture now.

  • PDUFA Nov 27 ’26 for neladalkib and Sep 18 ’26 for zidesamtinib could drive approvals
  • Total addressable oncology market >$150 B supports high revenue potential
  • Q2 EPS of -$6.06 and ROE -41% highlight severe losses
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICTREND
Sales, Adj.
YoY %
P / Sales
EV / Sales
Gross Profit, Adj.
YoY %
Margin %
EV / Gross Profit
EBITDA, Adj.
YoY %
Margin %
EV / EBITDA
EBIT
YoY %
Margin %
EV / EBIT
Net Income
YoY %
Net Margin
EPS (GAAP)
YoY %